CZ20011229A3 - Opthalmologické prostředky - Google Patents

Opthalmologické prostředky

Info

Publication number
CZ20011229A3
CZ20011229A3 CZ20011229A CZ20011229A CZ20011229A3 CZ 20011229 A3 CZ20011229 A3 CZ 20011229A3 CZ 20011229 A CZ20011229 A CZ 20011229A CZ 20011229 A CZ20011229 A CZ 20011229A CZ 20011229 A3 CZ20011229 A3 CZ 20011229A3
Authority
CZ
Czechia
Prior art keywords
ophthalmological preparations
ophthalmological
preparations
Prior art date
Application number
CZ20011229A
Other languages
English (en)
Other versions
CZ294385B6 (cs
Inventor
Napoli Guido Di
Original Assignee
Laboratoire Medidom S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Medidom S. A. filed Critical Laboratoire Medidom S. A.
Publication of CZ20011229A3 publication Critical patent/CZ20011229A3/cs
Publication of CZ294385B6 publication Critical patent/CZ294385B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ20011229A 2000-04-07 2001-04-04 Oftalmologické prostředky CZ294385B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH6942000 2000-04-07

Publications (2)

Publication Number Publication Date
CZ20011229A3 true CZ20011229A3 (cs) 2001-11-14
CZ294385B6 CZ294385B6 (cs) 2004-12-15

Family

ID=4529494

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011229A CZ294385B6 (cs) 2000-04-07 2001-04-04 Oftalmologické prostředky

Country Status (19)

Country Link
US (2) US6677304B2 (cs)
EP (1) EP1142566B1 (cs)
JP (1) JP2001316284A (cs)
CN (1) CN1185009C (cs)
AR (1) AR028291A1 (cs)
AT (1) ATE250924T1 (cs)
AU (1) AU778858B2 (cs)
BR (1) BR0101332A (cs)
CA (1) CA2342133C (cs)
CZ (1) CZ294385B6 (cs)
DE (1) DE60100866T2 (cs)
DK (1) DK1142566T3 (cs)
ES (1) ES2206363T3 (cs)
IL (1) IL142268A (cs)
PL (1) PL201055B1 (cs)
PT (1) PT1142566E (cs)
SK (1) SK285220B6 (cs)
TR (1) TR200302105T4 (cs)
ZA (1) ZA200102769B (cs)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1387676A2 (en) * 2001-05-01 2004-02-11 Angiotech Pharmaceuticals, Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7326256B2 (en) * 2002-12-06 2008-02-05 L'ORéAL S.A. Composition for the oxidation dyeing of keratin fibers, comprising at least one non-oxyalkenylated fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one amide of an alkanolamine and a C14-C30 fatty acid
FR2848106B1 (fr) * 2002-12-06 2006-11-17 Oreal Composition de teinture pour fibres keratiniques comprenant un alcool gras non oxyalkylene, un colorant d'oxydation, un polymere associatif et un amide d'une alcanolamine et d'un acide gras en c14-c30.
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
AU2003228126A1 (en) * 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
AU2005209201B2 (en) * 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
WO2006067608A1 (en) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
CN100478025C (zh) * 2005-03-25 2009-04-15 中国科学院上海药物研究所 一种环孢菌素a眼用微乳制剂及其制备方法
BRPI0612596A2 (pt) * 2005-07-01 2010-11-23 Sigma Tau Ind Farmaceuti uso de l-carnitina ou alcanoil-l-carnitinas para a preparação de um suplemento ou medicamento fisiológico para uso oftálmico na forma de gotas oftálmicas
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
WO2007043702A1 (en) * 2005-10-12 2007-04-19 Seikagaku Corporation Agent for applying to mucosa and method for production thereof
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
AU2006311577B2 (en) * 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
CN103214483B (zh) 2005-12-13 2014-12-17 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
CN103127100A (zh) 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
US20080015250A1 (en) * 2006-06-27 2008-01-17 Friedlaender Mitchell H Ultraviolet absorbing ophthalmic compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
EP2139492A1 (en) * 2007-03-30 2010-01-06 Fovea Pharmaceuticals SA Methods for treating neovascular ocular diseases
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA3014633C (en) 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
JP5640207B2 (ja) * 2007-10-08 2014-12-17 セラオプティクスＴｈｅｒａｏｐｔｉｃｓ 水性眼用処方物
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GB0904423D0 (en) * 2009-03-14 2009-04-29 Univ Strathclyde Improving the solubility of chemicals
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
ES2537385T3 (es) 2009-06-09 2015-06-08 Aurinia Pharmaceuticals Inc. Sistemas de suministro tópico para uso oftálmico
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR102283091B1 (ko) 2010-03-10 2021-07-30 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8785394B2 (en) * 2011-11-15 2014-07-22 Allergan, Inc. Sustained action formulation of cyclosporin form 2
WO2013074616A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
ES2837626T3 (es) 2013-07-10 2021-07-01 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
EP3030227B1 (en) 2013-08-07 2020-04-08 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CA2955037A1 (en) * 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
RU2727809C2 (ru) 2015-09-24 2020-07-24 Матрикс Байолэджи Инститьют Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
KR101635915B1 (ko) * 2016-02-15 2016-07-04 삼천당제약주식회사 사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
KR20190068575A (ko) * 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
PE20211310A1 (es) 2018-01-30 2021-07-22 Incyte Corp Procedimiento para la elaboracion de un recipiente de vidrio de sosa-cal a partir de materiales formadores de vidrio 100% reciclados y un recipiente de vidrio elaborado a partir de dicho procedimiento
EP3773330A4 (en) * 2018-03-29 2022-01-05 Mati Therapeutics Inc. FORMULATION ON DELAYED RELEASE OF OPHTHALMIC MEDICINAL PRODUCTS AND USES FOR TREATMENT OF DRY EYE
JP2021519775A (ja) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療
SG11202106967QA (en) * 2018-12-27 2021-07-29 Surface Ophthalmics Inc Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20220378698A1 (en) 2019-07-12 2022-12-01 Pharmathen S.A. Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
KR20220157405A (ko) * 2020-03-23 2022-11-29 키오라 파마슈티칼스, 인크. 안구 병태의 치료를 위한 조성물 및 방법
GR1010012B (el) 2020-05-12 2021-05-27 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11484538B2 (en) * 2020-08-26 2022-11-01 Somerset Therapeutics, Llc Bromfenac, prednisolone, and moxifloxacin compositions and methods
TW202412822A (zh) * 2022-07-20 2024-04-01 日商旭化成股份有限公司 玻尿酸衍生物醫藥組合物及醫藥組合物之製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US592048A (en) * 1897-10-19 Drill-press
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0756489B1 (en) * 1994-06-01 1999-08-18 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
JPH1160505A (ja) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd 防腐組成物

Also Published As

Publication number Publication date
DE60100866T2 (de) 2004-07-29
TR200302105T4 (tr) 2004-02-23
BR0101332A (pt) 2001-11-06
US6953776B2 (en) 2005-10-11
DE60100866D1 (de) 2003-11-06
CA2342133C (en) 2011-02-01
US20040106546A1 (en) 2004-06-03
PL346926A1 (en) 2001-10-08
AU778858B2 (en) 2004-12-23
IL142268A0 (en) 2002-03-10
CZ294385B6 (cs) 2004-12-15
PT1142566E (pt) 2004-02-27
EP1142566A1 (fr) 2001-10-10
ATE250924T1 (de) 2003-10-15
DK1142566T3 (da) 2004-02-09
AU3340401A (en) 2001-10-11
JP2001316284A (ja) 2001-11-13
PL201055B1 (pl) 2009-03-31
ZA200102769B (en) 2001-10-05
ES2206363T3 (es) 2004-05-16
SK4602001A3 (en) 2001-11-06
CN1185009C (zh) 2005-01-19
US6677304B2 (en) 2004-01-13
US20010041671A1 (en) 2001-11-15
EP1142566B1 (fr) 2003-10-01
SK285220B6 (sk) 2006-09-07
AR028291A1 (es) 2003-04-30
CN1317342A (zh) 2001-10-17
CA2342133A1 (en) 2001-10-07
IL142268A (en) 2007-08-19

Similar Documents

Publication Publication Date Title
CZ20011229A3 (cs) Opthalmologické prostředky
EP1329217A4 (en) SOLID PREPARATIONS
DE60141136D1 (en) Selektive photocoagulation
AU6282901A (en) Medical arrangement
AU2001252135A1 (en) Therapeutic agents
HK1068812A1 (en) Drug preparations
AU2001241963A1 (en) Improved medical procedure
PL359416A1 (en) Medicine comprising dicyanopyridine derivative
EP1296697A4 (en) THERAPEUTIC COMPOUNDS
GB0009591D0 (en) Medical combinations
AU6269101A (en) Cosmetic preparation
GB0011244D0 (en) Tissue regrafting
AU2002227925A1 (en) Human beta-defensin-3
AU2001270129A1 (en) Human phosphodiesterases
IL151523A0 (en) Use of avocado-soybean unsaponifiable preparations
AU2001273903A1 (en) Therapeutic agents
EP1260211A4 (en) SKIN CARE FOR EXTERNAL USE
GB0030541D0 (en) Medical uses
AU8252101A (en) Oct preparations
AU2001282521A1 (en) OCT preparations
GB0021487D0 (en) Pharmaceutical
AU2002214332A1 (en) Ophthalmological preparations
WO2002086124A8 (en) Human chemokine-13
AU2002231726A1 (en) Human 4-nitrophenylphosphatase
AU2001297783A1 (en) Human chemokine-13

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20150404